Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

Welcome to a very special edition of OncLive On Air! I’m your host today, Gina Columbus.

OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

But today, we had the pleasure of sitting down with Maurie Markman, MD, physician and president of medicine and science at Cancer Treatment Centers of America—and the editor-in-chief of our flagship publication, OncologyLive. Dr. Markman has conducted practice-changing research in ovarian cancer throughout his career. For starters, he was a leading investigator on the phase III Southwest Oncology Group and Gynecologic Oncology Group trial that established 12 cycles of single-agent paclitaxel as a new standard maintenance option for women with advanced ovarian cancer.

He has also been heavily involved in research efforts dedicaed to the use of weekly paclitaxel and treatment-free intervals for patients with ovarian cancer, and has helped to identify characteristics of patients best suited to receive intraperitoneal chemotherapy.

Not only has Dr. Markman served as a past chairman of the Giants of Cancer Care program, but in 2018, he was recognized as the OncLive Giant of Cancer Care® for Gynecologic Cancer for his tremendous achievements.

In our exclusive interview, Dr. Markman shared the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.